Hospital del Mar, Barcelona, Spain.
J Interv Cardiol. 2010 Jun;23(3):240-8. doi: 10.1111/j.1540-8183.2010.00547.x.
Calcified coronary lesions may be associated with stent underexpansion, malapposition, and high rates of restenosis. The use of drug-eluting stents (DES) in such lesions has not been fully addressed in the major trials. We sought to examine the outcomes of patients who were treated with plaque modification (PM) to facilitate DES implantation.
We analyzed 164 calcified coronary lesions in 145 consecutive patients who underwent aggressive PM with either rotational atherectomy (RA) and/or cutting balloon (CB) before DES implantation. CB was used in moderate calcified lesions and RA alone or followed by CB in severe calcified lesions.
Patients were 68.7 +/- 10.1 years old, 47% were diabetic, 34% had left ventricular ejection fraction (LVEF) < or =50%, and 39% had 3-vessel disease. Ninety-five percent of lesions were classified as B2/C, 100% as moderately/severely calcified. PM was achieved by using CB in 57% and by RA alone or followed by CB in 43%. In 100%, a DES was implanted. There was no failure to deliver a stent. At 15 +/- 11 months follow-up, the overall major adverse cardiac events (MACE) rate was 9.6% (3.4% cardiac death, 2.3% myocardial infarction, and 3.4% target lesion revascularization [TLR]). The only independent predictor of MACE was LVEF < or =50% (odds ratio 3.88; 95% confidence interval: 1.15-13.1; P = 0.03). The incidence of stent thrombosis (ST) was 2.1%. There were no significant differences in MACE and TLR based on the type of PM used.
In this population at high risk of restenosis, aggressive PM by CB and/or RA before DES implantation provides excellent mid-term outcomes with only 3.4% TLR and 2.1% ST.
钙化的冠状动脉病变可能与支架扩张不足、贴壁不良以及再狭窄率高有关。在主要临床试验中,尚未充分研究药物洗脱支架(DES)在这些病变中的应用。我们旨在研究经斑块修饰(PM)以促进 DES 植入的患者的结局。
我们分析了 145 例连续患者的 164 个钙化冠状动脉病变,这些患者在 DES 植入前均接受了积极的 PM,包括旋磨术(RA)和/或切割球囊(CB)。CB 用于中度钙化病变,RA 单独使用或在严重钙化病变中联合 CB 使用。
患者的年龄为 68.7 ± 10.1 岁,47%为糖尿病患者,34%左心室射血分数(LVEF)≤50%,39%为三支血管病变。95%的病变被归类为 B2/C,100%为中重度钙化。57%的患者通过 CB 实现 PM,43%的患者通过 RA 单独或联合 CB 实现 PM。100%的患者植入了 DES。没有支架输送失败的情况。在 15 ± 11 个月的随访中,总的主要不良心脏事件(MACE)发生率为 9.6%(3.4%心脏死亡,2.3%心肌梗死,3.4%靶病变血运重建[TLR])。MACE 的唯一独立预测因素是 LVEF≤50%(优势比 3.88;95%置信区间:1.15-13.1;P=0.03)。支架血栓形成(ST)的发生率为 2.1%。基于使用的 PM 类型,MACE 和 TLR 没有显著差异。
在这种高再狭窄风险的人群中,在 DES 植入前通过 CB 和/或 RA 进行积极的 PM 可提供出色的中期结果,仅 3.4%的 TLR 和 2.1%的 ST。